Myovant Sciences Ltd (MYOV) Now Covered by JMP Securities
JMP Securities began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Monday. The brokerage set an “outperform” rating and a $23.00 price target on the stock. JMP Securities’ target price indicates a potential upside of 108.52% from the company’s previous close.
A number of other equities analysts have also recently commented on MYOV. Barclays PLC assumed coverage on shares of Myovant Sciences in a research note on Monday. They issued an “overweight” rating and a $18.00 price objective for the company. Robert W. Baird assumed coverage on shares of Myovant Sciences in a research note on Monday. They issued an “outperform” rating and a $20.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Myovant Sciences presently has a consensus rating of “Buy” and a consensus target price of $20.33.
Myovant Sciences (NASDAQ:MYOV) opened at 11.03 on Monday. The company’s market cap is $480.80 million. The stock has a 50 day moving average of $11.40 and a 200 day moving average of $11.40. Myovant Sciences has a 12-month low of $10.26 and a 12-month high of $13.31.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.